 Home > Active Ingredient News > Endocrine System > Diabetes Obes Metab: The effect of SGLT-2 inhibitors on serum uric acid levels in patients with T2DM

Diabetes Obes Metab: The effect of SGLT-2 inhibitors on serum uric acid levels in patients with T2DM

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

crispr review

error analysis chemistry

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, a research article was published in Diabetes Obesity & Metabolism, an authoritative journal in the field of metabolic endocrine diseases, which aims to determine the effect of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on serum uric acid in Asian type 2 diabetes (T2DM) patients (SUA) level of influence
.

diabetes

The researchers searched PubMed, CENTRAL, Embase, and Cochrane Library databases published as of July 15, 2021 for randomized controlled trials (RCTs) evaluating the efficacy of SGLT-2 inhibitors in patients with T2DM.
There are no language or date restrictions
.

A total of 19 high-quality studies (4218 participants) were included in the network meta-analysis
.

Compared with the control group, T2DM patients were treated with all included SGLT-2 inhibitors (enpagliflozin, dapagliflozin, canagliflozin, impagliflozin, rosagliflozin, and togliflozin).

Subgroup analysis and meta-regression indicate that the combined analysis of different inhibitors may lead to heterogeneity of results
.

Therefore, among SGLT-2 inhibitors, follow-up network meta-analysis results show that among SGLT-2 inhibitors, rosagliflozin and dapagliflozin rank the highest in reducing SUA levels

It can be seen that SGLT-2 inhibitors can significantly reduce the level of SUA in patients with T2DM, among which rosagliflozin (1mg and 10mg) and dapagliflozin (5mg) have the best effect
.

Therefore, SGLT-2 inhibitors look very promising as an anti-diabetic treatment option for T2DM patients with higher SUA levels

SGLT-2 inhibitors can significantly reduce the level of SUA in patients with T2DM, among which rosagliflozin (1mg and 10mg) and dapagliflozin (5mg) have the best effect
.
Therefore, SGLT-2 inhibitors look very promising as an anti-diabetic treatment option for T2DM patients with higher SUA levels
.
Original Source: Effects of SGLT-2 inhibitors ON URIC acid serum in patients with T2DM: A Systematic Review and Meta-Network the Analysis in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.